Supplementary Materials

Supplementary Material for:

Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention

Scott N. Furlan, Benjamin Watkins, Victor Tkachev, Ryan Flynn, Sarah Cooley, Swetha Ramakrishnan, Karnail Singh, Cindy Giver, Kelly Hamby, Linda Stempora, Aneesah Garrett, Jingyang Chen, Kayla M. Betz, Carly G. K. Ziegler, Gregory K. Tharp, Steven E. Bosinger, Daniel E. L. Promislow, Jeffrey S. Miller, Edmund K. Waller, Bruce R. Blazar, Leslie S. Kean*

*Corresponding author. E-mail: leslie.kean{at}

Published 25 November 2015, Sci. Transl. Med. 7, 315ra191 (2015)
DOI: 10.1126/scitranslmed.aad3231

This PDF file includes:

  • Fig. S1. Sorting strategy and purity of T cells destined for microarray analysis.
  • Fig. S2. Successful batch effect correction for PCA.
  • Fig. S3. GSEA performed using previously published gene sets related to LCMV infection reveals commonality between T cell activation in response to alloactivation and acute viral infection.
  • Fig. S4. Selected dysregulation of TH17-associated transcripts.
  • Fig. S5. AURKA interactome shows little overlap with the leading edge genes in the LCMV GSEA analyses.
  • Fig. S6. Translational pipeline for GVHD pathway discovery.
  • Fig. S7. Investigation of SHH pathway enrichment in GVHD Table S1. Transplant cell doses for autologous and allogeneic transplant recipients.
  • Legend for tables S2 to S5
  • Table S6. Clinical characteristics of transplant patients.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S2 (Microsoft Excel format). Top gene analysis—Top 200 over- or underrepresented transcripts during GVHD in NHP: Comparison between the No Rx and autologous controls.
  • Table S3 (Microsoft Excel format). GSEA results—Gene sets enriched in No Rx versus autologous controls.
  • Table S4 (Microsoft Excel format). DAVID pathway analysis of the combined leading edge genes found in the No Rx versus autologous controls from the LCMV gene sets depicted in Fig. 4C and fig. S3.
  • Table S5 (Microsoft Excel format). DAVID pathway analysis of transcripts differentially expressed between the No Rx and autologous controls.
  • Data S1 (Microsoft Excel format). Spreadsheet with raw NHP clinical score data, NHP survival data, NHP chimerism data, murine clinical score data, murine survival data, and human MLR gene expression data (Figs. 1, B to D, and 8, A to C).
  • Data S2 (Microsoft Excel format). Spreadsheet with raw flow cytometric data from Figs. 1E and 5D.

[Download Tables S2 to S5]

[Download Data S1 and S2]